|
211 |
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo
Enthalten in Cancer immunology immunotherapy Bd. 64, 15.10.2015, Nr. 12, date:12.2015: 1575-1586
|
|
|
|
212 |
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia
Enthalten in Annals of hematology Bd. 103, 18.7.2024, Nr. 9, date:9.2024: 3429-3442
|
|
|
|
213 |
PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation
Enthalten in Clinical epigenetics Bd. 12, 20.8.2020, Nr. 1, date:12.2020: 1-14
|
|
|
|
214 |
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
Enthalten in Annals of hematology Bd. 99, 19.4.2020, Nr. 6, date:6.2020: 1241-1249
|
|
|
|
215 |
Revesz syndrome revisited
Enthalten in Orphanet journal of rare diseases Bd. 15, 23.10.2020, Nr. 1, date:12.2020: 1-13
|
|
|
|
216 |
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
Enthalten in Leukemia Bd. 37, 7.9.2023, Nr. 11, date:11.2023: 2282-2285
|
|
|
|
217 |
Sollen Kinder onkologischer Patienten während der COVID-19-Pandemie Kitas oder Schulen besuchen?
Enthalten in Der Onkologe Bd. 27, 25.1.2021, Nr. 3, date:3.2021: 282-286
|
|
|
|
218 |
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Enthalten in Journal of experimental & clinical cancer research Bd. 43, 8.11.2024, Nr. 1, date:12.2024: 1-15
|
|
|
|
219 |
Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies
Enthalten in British journal of cancer Bd. 130, 17.1.2024, Nr. 6, date:4.2024: 1013-1022
|
|
|
|
220 |
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Enthalten in Annals of hematology Bd. 102, 18.8.2023, Nr. 10, date:10.2023: 2741-2752
|
|
Administration
